That is a critical issue that is fundamentally different than what we see in Western Europe and that we will see in the United States. |
The surveillance is going to be so intense that it is very unlikely that there is going to be the type of situation we see everywhere from Nigeria to Indonesia. |
We are tending much more towards making sure that we have pharmaceutical plants that are located on U.S. soil, so that we don't have a situation where if you have a global pandemic, then countries would obviously be nationalizing [their] factories. So, we want to work with other companies. We want to work with other countries. We want to work with international as well as domestic companies, but we don't want to have everything that we are doing be done outside of the United States, which is almost what is the situation right now. |
We have a long way to go. |
We have a vaccine we know can spur an immune response, albeit at very high doses. We're going in the right direction. The sobering news is we have a long way to go. So it's muted good news. |
We hoped to see a 75 percent response rate, but the fact it came in at 50 percent is not way out of line for our expectations. |
We're aiming at 20-million doses of a pre-pandemic vaccine but to develop the capacity to be able to make 300-million doses within six months of when we ultimately get the latest version of it that is the real killer. |
With seasonal flu, the response rate in healthy young adults ranges from 60 to 90 percent. We all hoped for 70 percent with this vaccine, but it wasn't to be. The next step is to give a booster to those who failed to respond, which we're already doing. Earlier studies have shown a third shot often increases immunity dramatically. |